Healthcare Industry News: Inspiration Biopharmaceuticals
News Release - November 19, 2007
Cook Pharmica Signs Agreement with Inspiration Biopharmaceuticals for the Transfer of its Clinical Manufacturing Process for Lead Hemophilia CompoundBLOOMINGTON, Ind.--(HSMN NewsFeed)--Cook Pharmica, the contract biopharmaceutical manufacturing and development services division of Cook Medical, announced today that it has signed an agreement with Inspiration Biopharmaceuticals, to conduct development work for its lead biologic therapy, an intravenous Factor IX product for patients with hemophilia B. Activities will be performed in Cook Pharmica’s development laboratory within its Bloomington, Ind. facility.
“We are very excited to join with Inspiration Biopharmaceuticals as their contract service provider and help bring this crucial therapy to patients,” said Jerry Arthur, president of Cook Pharmica. “This is another significant milestone for Cook Pharmica and we look forward to partnering with this innovative company.”
“We are pleased to be working with Cook Pharmica,” said Michael Griffith, Ph.D., President and CEO, Inspiration Biopharmaceuticals. “We look forward to our partnership as we prepare for large scale manufacturing of our Factor IX product for the treatment of hemophilia B.”
Terms of the agreement were not released.
About Cook Pharmica:
Cook Pharmica (www.cookpharmica.com) is a contract biopharmaceutical manufacturing organization developing and manufacturing mammalian cell culture-based pharmaceuticals for pre-clinical through commercial use. They also offer cell line/strain development, clone selection, cell line adaptation, media optimization, process development, analytical development, cell banking/storage, stability testing/storage, and regulatory submission support.
About Cook Medical
Cook Medical, the world’s largest privately held medical device company with 15 manufacturing facilities and more than 6,000 employees worldwide, has pioneered countless innovative minimally invasive interventional technologies for diagnostic and therapeutic procedures and is leading the way in the convergence of devices, drug-eluting coatings, bio-derived materials, and cell and gene therapies that will further benefit patients in the 21st Century. One of the fastest-growing medical technology companies in the world since its founding in 1963, Cook is recognized as a leading developer, manufacturer and global distributor of cutting-edge interventional therapies in the fields of radiology, cardiology, urology, aortic intervention, peripheral intervention including peripheral vascular, bone access and oncology, women’s health and other gender-specific procedures, critical care medicine, surgery and soft tissue repair, gastroenterology, and cellular and genetic therapies. With global headquarters in Bloomington, Ind., the company won the prestigious Medical Device Manufacturer of the Year Award for 2006 from Medical Device & Diagnostic Industry magazine. For more information, visit (www.cookmedical.com)
About Inspiration Biopharmaceuticals
Founded in 2004, Inspiration Biopharmaceuticals is focused on revolutionizing the treatment of hemophilia through production of lower cost versions of existing intravenous recombinant therapies and development of non-invasive applications to enhance prophylactic administration. The Company’s first product candidate is to be a less costly intravenous presentation of recombinant Factor IX. The proposed second generation product is a non-injectable recombinant Factor IX, designed specifically for prophylactic therapy.
Source: Cook Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.